Nektar Therapeutics (NKTR) has launched the first two global Phase 3 ZENITH AD trials for rezpegaldesleukin in moderate to severe atopic dermatitis, supported by earlier Phase 2b data and FDA Fast Track designations.

The latest rezpegaldesleukin Phase 3 launch comes after a sharp shift in sentiment around Nektar Therapeutics, with a 1-year total shareholder return of 199.05% and a year to date share price return of 62.89%. However, momentum has eased more recently, with the 90 day share price return down 15.61%.

If this kind of biotech catalyst has your attention, it could be a good moment to scan for other healthcare and AI opportunities using our dedicated screener for 40 healthcare AI stocks

After Nektar Therapeutics’ sharp rebound and the recent pullback, the decision is simple but not easy: lean into the current price after this Phase 3 news, or wait for a cheaper entry. The valuation work starts here.

Most Popular Narrative: 54% Undervalued

The most followed narrative on Nektar Therapeutics pegs fair value at $153.25 per share versus a last close of $70.73, framing the current price as a steep discount and putting the Phase 3 rezpegaldesleukin story at the center of that gap.

Strong initial Phase IIb and ongoing data for REZPEG in atopic dermatitis, combined with a large and growing addressable market (expected to reach nearly $30B by 2033), position Nektar to access significant new revenue streams and improve long-term earnings as the population ages and chronic inflammatory diseases rise globally.

The fair value hinges on a detailed earnings path, a sharp margin shift and a future profit multiple that is far from ordinary. Want to see which assumptions do the heavy lifting and how they fit together in this Nektar Therapeutics story?

Result: Fair Value of $153.25 (UNDERVALUED)

However, Nektar Therapeutics still faces real pressure from ongoing losses and heavy reliance on rezpegaldesleukin outcomes, with future funding needs representing another potential swing factor.

Another View: What Nektar Therapeutics’ Sales Multiple Is Telling You

While the most followed Nektar Therapeutics narrative points to a fair value of $153.25 per share, the current P/S ratio of 43x sends a very different signal. It sits far above the US Pharmaceuticals industry at 4.9x, peers at 10.7x, and even the fair ratio estimate of 16.9x.

That kind of gap suggests the market is already pricing in a lot of future success. This can mean less room for error if rezpegaldesleukin or the broader pipeline fall short. How much optimism are you really comfortable baking into the story?

Next Steps

With Nektar Therapeutics pulling investors in different directions, do you want to rely on headline narratives or test the data yourself and move quickly to shape your own view using the 1 key reward and 3 important warning signs?

Looking for more investment ideas beyond Nektar Therapeutics?

If you are serious about sharpening your next move after Nektar Therapeutics, do not stop at one stock; expand your watchlist with focused, data driven screens.

• Target potential breakout opportunities by scanning 20 elite penny stocks with strong financials that combine low share prices with stronger underlying financials than many expect.
• Zero in on quality at a discount by reviewing 50 high quality undervalued stocks that pair healthier balance sheets with pricing that looks out of sync with fundamentals.
• Prioritize resilience and capital protection by checking 84 resilient stocks with low risk scores that score well on risk metrics so you are not caught off guard by surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.